Variant status may impact FADS2 expression and consequently the levels of PUFAs within cells and the inflammatory signalling through eicosanoids, and these pathway have been suggested as resolving mediators in chronic inflammatory disorders like atherosclerosis and the investigated immune-mediated disorders[55]. The gene discussed is FADS2; the disease is atherosclerosis.